We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Key Charpentier/Doudna CRISPR Patent Upheld by Japanese Patent Office

Double helix structure of DNA.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced its second Japanese Patent (JP6692856) was upheld for the second time, in response to an invalidation challenge.

The patent, filed by Dr. Charpentier, together with The Regents of the University of California and University of Vienna (collectively known as CVC), was also upheld previously by the Japanese Patent Office (JPO) in 2021.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

During the proceedings, novelty and inventive step were contested. In the decision, the JPO rejected both challenges to patentability, fully upholding the patent and further demonstrating its validity and value as part of the patent collection for use of the CRISPR/Cas9 technology.

Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: The decision by the JPO reinforces our foundational patents to CRISPR/Cas9 and highlights the value of ensuring the correct intellectual property is in place when working with this fundamental technology. This re-affirmation of the validity of our fundamental CRISPR patents supports our active licensing efforts in Japan and ensures greater value to new and existing licensees there.”

ERS Genomics provides licensing to CRISPR/Cas9 technology for companies interested in pursuing its use in their commercial programs. With 89 patents held in over 90 countries, ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide.